Advancing Tobacco Use Treatment for African American Smokers

The purpose of this study is to examine whether or not providing Chantix (varenicline) will
help African American smokers quit smoking.

Eligibility Criteria

Inclusion Criteria:

- Self-identified African American

- Smokes ≥ 1 cigarette per day (cpd)

- Smoke on ≥ 25 days of the past 30 days

- Functioning telephone

- Interested in quitting smoking

- Interested in taking 3 months of varenicline

- Willing to complete all study visits

Exclusion Criteria:

- Renal impairment

- Evidence or history of clinically significant allergic reactions to varenicline

- A cardiovascular event in the past month

- History of alcohol or drug dependence in the past year

- Major depressive disorder in the last year requiring treatment

- History of panic disorder, psychosis, bipolar disorder, or eating disorders

- Use of tobacco products other than cigarettes in past 30 days

- Use of pharmacotherapy in the month prior to enrollment, including prior use of
varenicline

- Pregnant, contemplating getting pregnant, or breastfeeding

- Plans to move from Kansas City during the treatment and follow-up phase

- Another household member enrolled in the study

- Evidence of current severe major depressive disorder or suicidal ideation

Principal Investigator

Lisa Sanderson Cox, PhD

Study Contact

Tricia Snow, MPH, psnow@kumc.edu, 816-627-2121

Estimated Completion Date

Saturday, December 1, 2018

ClinicalTrials.gov #

NCT02360631
05/17/2015